Lazard Research & Insights


Back Clear all Clear

Healthcare leaders are entering 2026 with cautious optimism and a sharper focus on execution — even as the imperative to deploy capital remains intense.


January 05, 2026

Annual Review of Shareholder Activism 2025

Lazard’s 2025 Review of Shareholder Activism highlights key trends and data in shareholder activism activity throughout the year.

January 08, 2026

Lazard 2025 M&A Review and 2026 Outlook

Today, Lazard published its 2025 M&A Review and 2026 Outlook Report examining the historical quantitative and qualitative drivers of M&A, the additional factors that accelerated activity in 2025, and the emerging themes that could shape dealmaking in the year ahead.